Evolus Raises FY24 Net Revenue Guidance From $255M - $265M To $260M - $270M, Est $262.495M
Evolus Raises FY24 Net Revenue Guidance From $255M - $265M To $260M - $270M, Est $262.495M
evolus將 FY24 淨營業收入指引從 25500萬 - 26500萬 增至 26000萬 - 27000萬，預計爲 262.495M。
- The company continues to expect its adjusted gross profit margin for the full year 2024 to be between 68% and 71%.
- The company continues to expect to achieve positive non-GAAP operating income on a consolidated basis for the fourth quarter of 2024 and for the full year 2025.
- The company projects its total net revenue can reach at least $700 million by 2028, a compound annual growth rate of 28% from 2023, based on the combination of its existing aesthetic neurotoxin business and anticipated launch of the Evolysse HA dermal filler product line beginning in 2025.
- 公司繼續預計其2024財年的調整毛利潤率將在68%至71%之間。
- 公司繼續預計在2024財年第四季度和2025財年整體上實現正的非GAAP營業收入。
- 公司預計，基於其現有的美學神經毒素業務和預計於2025年開始推出的Evolysse HA皮膚填充產品系列，其總淨營業收入至少可達到2028 年$70,000萬，複合年增長率爲28%。
資訊熱榜
更新時間